Evidence map›Paper›PMID 38842525›Full record

ArticleThe Journal of experimental medicine2024

Ki67 deficiency impedes chromatin accessibility and BCR gene rearrangement.

Zhoujie Ding, Maree Hagan, Feng Yan, Nick W Y Schroer, Jack Polmear, Kim L Good-Jacobson, Alexandra R Dvorscek, Catherine Pitt, Kristy O'Donnell, Stephen L Nutt and 7 more

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zhoujie Ding *Department of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-8765-8814
Maree Hagan *Ozgene Pty Ltd. , Bentley, Australia.ORCID 0000-0003-2379-3552
Feng YanBioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0002-8848-1739
Nick W Y SchroerDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0009-0007-5648-4605
Jack PolmearDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Australia.ORCID 0000-0003-3449-4128
Kim L Good-JacobsonDepartment of Biochemistry and Molecular Biology, Monash University, Clayton, Australia.ORCID 0000-0003-1891-7274
Alexandra R DvorscekDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0002-8617-2422
Catherine PittDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-6256-8185
Kristy O'DonnellDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0003-1964-4685
Stephen L NuttImmunology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.ORCID 0000-0002-0020-6637
Dimitra ZotosDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0009-0002-7087-9084
Craig McKenzieDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-7070-620X
Danika L HillDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-6284-7061
Marcus J RobinsonDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-5677-3078
Isaak QuastDepartment of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-6517-8537
Frank Koentgen *Ozgene Pty Ltd. , Bentley, Australia.ORCID 0000-0002-5660-4028
David M Tarlinton *Department of Immunology, Central Clinical School, Monash University, Melbourne, Australia.ORCID 0000-0001-9928-686X

Funding

Cancer Council VictoriaMASSIVEMonash UniversityNational Health and Medical Research Council APP1175411NectarSwedish Research Council 2016-06659Swiss National Science Foundation P300PA_177893
6 · The paper itself

Abstract

The proliferation marker Ki67 has been attributed critical functions in maintaining mitotic chromosome morphology and heterochromatin organization during the cell cycle, indicating a potential role in developmental processes requiring rigid cell-cycle control. Here, we discovered that despite normal fecundity and organogenesis, germline deficiency in Ki67 resulted in substantial defects specifically in peripheral B and T lymphocytes. This was not due to impaired cell proliferation but rather to early lymphopoiesis at specific stages where antigen-receptor gene rearrangements occurred. We identified that Ki67 was required for normal global chromatin accessibility involving regulatory regions of genes critical for checkpoint stages in B cell lymphopoiesis. In line with this, mRNA expression of Rag1 was diminished and gene rearrangement was less efficient in the absence of Ki67. Transgenes encoding productively rearranged immunoglobulin heavy and light chains complemented Ki67 deficiency, completely rescuing early B cell development. Collectively, these results identify a unique contribution from Ki67 to somatic antigen-receptor gene rearrangement during lymphopoiesis.

Indexed as

B-LymphocytesChromatinKi-67 AntigenAnimalsCell ProliferationGene RearrangementHomeodomain ProteinsLymphopoiesisMiceMice, Inbred C57BLReceptors, Antigen, B-CellT-LymphocytesChromatinHomeodomain ProteinsKi-67 AntigenRAG-1 proteinReceptors, Antigen, B-Cell

Identifiers

PMID38842525
PMCPMC11157087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.